THE PROPOSITION
1
In practice: does the molecule carry a receptor moiety? That is what anchors it in the gut wall or portal vein or liver rather than letting it wash straight through.
2
BOTH YES
An intestinal depot effect forms, half-life about 48 hours. Apparent bioavailability in the outer circulation is low; biopotency is high. Reading the plasma PK and concluding the formulation failed is the commonest error in this field.
EITHER NO
Living with obesity, diabetes, osteoporosis, arthritis and other chronic disorders often means lifelong treatment – impacting not only health, but daily life.
Despite important medical progress, many therapies come with trade-offs, including tolerability challenges, inconvenience, and inconsistent adherence.
Advancing treatment approaches that better align with patient needs remains essential.
Driving the future of metabolic and other diseases
Axcess is driven by a team of experienced scientists, healthcare innovators, and biotechnology professionals dedicated to improving diabetes treatment. Founded by experts in pharmaceutical research, drug delivery technologies, and healthcare entrepreneurship, the company combines strong scientific knowledge with commercial expertise. Together, the team focuses on developing innovative oral therapies that aim to transform how diabetes, obesity, cardiovascular and other diseases are managed worldwide.
Driving the future of diabetes treatment
Diabetology is driven by a team of experienced scientists, healthcare innovators, and biotechnology professionals dedicated to improving diabetes treatment. Founded by experts in pharmaceutical research, drug delivery technologies, and healthcare entrepreneurship, the company combines strong scientific knowledge with commercial expertise. Together, the team focuses on developing innovative oral therapies that aim to transform how diabetes is managed worldwide.
June 8, 2026
News
Diabetology Limited presents first-in-human oral capsule, intestinally absorbed GLP1 RA data at ADA 86th Scientific Sessions...
Read More
NOvember 11, 2025
Publication
The objective of this paper is to demonstrate that oral insulin is potentially close to being commercialized, in light of the fact that (i) the technical, safety, and pharmacological obstacles in developing an oral insulin for clinical use for diabetes can potentially be overcome, and (ii) there are players in the field that are moving an oral insulin formulation into advanced clinical trials.
Read More
July 5, 2025
Press Release
Lifesciences Magazine: Battling Diabetes! Exclusive Interview with the Glen Travers (Co-founder of Diabetology Limited), Leading Biopharma Company Pushing Boundaries
Read More
Axcess Limited
Axcess (UK) Limited
